Executive Bio
Dr. Amarpreet Sawhney, also known as Amar, Ph.D. is a Co-Founder and Managing Partner of Incept, LLC. Dr. Sawhney founded Ocular Therapeutix, Inc in November 2006 has been its Executive Chairman since June 2014. Dr. Sawhney served as Chief Executive Officer and President at Ocular Therapeutix, Inc since 2006 until 2017. He served as an Advisor at Axtria, Inc. He served as the President and Chief Executive Officer at Confluent Surgical, Inc. He is the President and Chief Executive Officer at Octux, Inc. He founded Augmenix, Inc. and also served as its Chief Executive Officer and President. He is the Founder, Chief Executive Officer and President at Ocular Therapeutix Inc. He founded Access Closure, Inc. and Octux, Inc. He co-founded Confluent Surgical, Inc. in 1998. Dr. Sawhney was the Technology Founder at Focal Inc. of Lexington, Massachusetts (acquired by Genzyme). He co-invented Novacell of Santa Ana, California. He serves as the Chairman of Augmenix, Inc. He served as the Chairman of marketRx, Inc. He serves as Executive Director for Instylla, Inc. He has been a Director of Ocular Therapeutix, Inc. since 2006. He serves as a Director of Axtria, Inc. He serves as a Director of Confluent Surgical, Inc. and marketRx, Inc. Dr. Sawhney served as Board Member of Octux, Inc., Augmenix, Inc., and Incept LLC. He served as a Director of Access Closure, Inc. and Focal Inc. He personally holds over 35 patents and has authored over 85 publications and scientific abstracts. He has been recognized by several awards including the MIT Global Indus Technovators award and the E&Y Regional Entrepreneur of the year award. His innovations are the subject of almost 100 issued and pending patents in biomaterials. His inventions include ???first-of-a-kind??? surgical sealants to be approved by the Food and Drug Administration. Dr. Sawhney holds a Ph.D. and a M.S. in Chemical Engineering from the University of Texas at Austin. He holds a B. Tech. in Chemical Engineering from the Indian Institute of Technology, New Delhi.